AffyImmune Therapeutics is a biopharmaceutical company developing genetically engineered immune cells to fight cancer.
AffyImmune Therapeutics has raised $20.0M in total funding. The most recent round was Series A. The last funding was announced in October 2021.
AffyImmune Therapeutics's investors include ORI Capital.
AffyImmune Therapeutics is headquartered in Newton, United States.
AffyImmune Therapeutics is a biopharmaceutical company developing genetically engineered immune cells to fight cancer.
AffyImmune Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AffyImmune Therapeutics — Funding & Investors." VCBacked, October 7, 2021, https://www.vcbacked.co/company/affyimmune-therapeutics. Accessed August 14, 2026.
VCBacked. (2021). AffyImmune Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/affyimmune-therapeutics
{{cite web |title=AffyImmune Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/affyimmune-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated